Press Releases

-- Revumenib is the first and only investigational treatment for R/R KMT2Ar acute leukemia to receive Breakthrough Therapy Designation -- -- Designation is based on Phase 1 data from the AUGMENT-101 trial that showed a 27% CR/CRh rate in KMT2A patients treated at RP2D -- -- Company remains on track

– Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all patients; and an ORR of 82% in patients dosed at 1 mg/kg every 2 weeks in the Phase 2 portion of the trial – – Broad multi-organ clinical benefit including in lung, skin, and joints and fascia observed in

WALTHAM, Mass. , Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5,

WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI

– Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months – – Enrollment complete in pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD – – Company remains on track for two U.S.

- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events - -  Median duration of CR/CRh response of 9.1 months - -  9 of 12 patients who underwent stem cell transplant after achieving a response

WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on

– On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 – – Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q22 – – Company to host conference call today at 4:30 p.m. ET – WALTHAM, Mass. , Aug.

WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2022 financial results on Monday, August 8 , after the

WALTHAM, Mass. , June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A.

WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two

WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.